{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Squamous+Cell+Carcinoma&page=3",
    "query": {
      "condition": "Metastatic Squamous Cell Carcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 791,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Squamous+Cell+Carcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Squamous+Cell+Carcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T02:38:25.550Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04925284",
      "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "SCCHN",
        "Pancreatic Cancer",
        "Esophageal SCC",
        "Metastatic Castration-resistant Prostate Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Epithelial Ovarian Cancer",
        "Endometrial Cancer",
        "Tissue Factor-Expressing Solid Tumors"
      ],
      "interventions": [
        {
          "name": "XB002",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 269,
      "start_date": "2021-06-07",
      "completion_date": "2025-03-10",
      "has_results": false,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04925284"
    },
    {
      "nct_id": "NCT03452332",
      "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cervical Adenocarcinoma",
        "Advanced Vaginal Carcinoma",
        "Advanced Vulvar Carcinoma",
        "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma",
        "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma",
        "Metastatic Cervical Adenocarcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Metastatic Vaginal Adenocarcinoma",
        "Metastatic Vaginal Carcinoma",
        "Metastatic Vulvar Carcinoma",
        "Recurrent Cervical Adenocarcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Recurrent Vaginal Carcinoma",
        "Recurrent Vulvar Carcinoma",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Vaginal Cancer AJCC v8",
        "Stage III Vulvar Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Vulvar Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Vulvar Cancer AJCC v8",
        "Stage IIIC Vulvar Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVA Vulvar Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8",
        "Stage IVB Vulvar Cancer AJCC v8",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Adenocarcinoma",
        "Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2018-07-18",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452332"
    },
    {
      "nct_id": "NCT03498378",
      "title": "Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kathryn Gold",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-06-06",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03498378"
    },
    {
      "nct_id": "NCT00514943",
      "title": "BIBW 2992 (Afatinib) in Head & Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Carcinoma, Squamous Cell"
      ],
      "interventions": [
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2007-08",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2016-07-26",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 18,
      "location_summary": "Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00514943"
    },
    {
      "nct_id": "NCT02109016",
      "title": "A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Squamous Non-Small Cell Lung Cancer",
        "NSCLC",
        "Small Cell Lung Cancer",
        "SCLC",
        "Lung Cancer",
        "Advanced Lung Cancer",
        "Metastatic Lung Cancer",
        "Stage IV Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lucitanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clovis Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-04",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2019-07-29",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109016"
    },
    {
      "nct_id": "NCT03978689",
      "title": "A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "CUE-101",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA®, Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cue Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2019-07-30",
      "completion_date": "2026-01-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978689"
    },
    {
      "nct_id": "NCT07169734",
      "title": "A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Squamous Cell Carcinoma",
        "Squamous Non-small-cell Lung Cancer",
        "Colorectal Cancer",
        "Intrahepatic Cholangiocarcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "ALE.P03",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alentis Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2025-08-26",
      "completion_date": "2029-10-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169734"
    },
    {
      "nct_id": "NCT05980000",
      "title": "Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Head and Neck Cancer",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Carcinoma",
        "Metastatic Head-and-neck Squamous-cell Carcinoma",
        "Metastatic Head and Neck Cancer",
        "HNSCC"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2023-10-27",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05980000"
    },
    {
      "nct_id": "NCT02318771",
      "title": "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Renal Cell Cancer",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Skin Carcinoma",
        "Stage III Renal Cell Cancer",
        "Stage IV Lung Cancer",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy (RT)",
          "type": "RADIATION"
        },
        {
          "name": "MK-3475",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2015-02-05",
      "completion_date": "2021-03-25",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02318771"
    },
    {
      "nct_id": "NCT03108131",
      "title": "Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Skin Squamous Cell Carcinoma",
        "Appendix Adenocarcinoma",
        "Rare Lesion",
        "Locally Advanced Malignant Neoplasm",
        "Locally Advanced Skin Squamous Cell Carcinoma",
        "Metastatic Malignant Neoplasm",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Metastatic Small Intestinal Adenocarcinoma",
        "Rare Neoplastic Syndrome",
        "Refractory Malignant Neoplasm",
        "Stage IV Small Intestinal Adenocarcinoma AJCC v8",
        "Unresectable Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2017-04-07",
      "completion_date": "2024-04-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-03T02:38:25.550Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108131"
    }
  ]
}